President Trump Increases Medical Marijuana and CBD Research
Impact Score: 3.4
Timeline: N/A: No explicit deadlines specified
Summary: On December 18, 2025, President Trump signed an Executive Order to enhance medical marijuana and cannabidiol (CBD) research, including rescheduling marijuana to Schedule III to facilitate studies. The order directs collaboration with Congress to ensure safe access to full-spectrum CBD products and emphasizes using real-world evidence to improve research methodologies. The initiative aligns with broader healthcare reforms, including drug pricing transparency and rural healthcare expansion. Vanderbilt University stands to benefit through research funding opportunities and integration of cannabinoid science into its programs, while federal agencies such as DOJ, HHS, and FDA play key roles in implementation.
Key Actions: Vanderbilt should pursue collaboration with federal entities and pharmaceutical companies, develop real-world evidence models, monitor legislation, update medical curricula, and explore research on cannabinoid impacts, particularly for seniors and vulnerable populations.
View Full Report
